The biologic agents that selectively inhibit the action of proinflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin (IL) 1, and IL6 have been successfully used for the treatment of AOSD refractory to conventional therapies that in turn reinforce the importance of excess of proinflammatory cytokines in the pathogenesis of AOSD [1, 2]. Here, IL6 is linked to adult-onset Still disease.